Summit Therapeutics (SMMT) Invested Capital (2018 - 2019)

Summit Therapeutics' (SMMT) quarterly Invested Capital came in at $10.3 million in Q4 2019, up 733.13% on a QoQ basis from $1.2 million in Q4 2019.

Summit Therapeutics (SMMT) Invested Capital (2018 - 2019) Analysis & Trends

Summit Therapeutics (SMMT) has 2 years of Invested Capital data on file, last reported at $10.3 million in Q4 2019.

Quarterly Invested Capital changed N/A year-over-year to $10.3 million in Q4 2019, while the trailing twelve-month figure through Sep 2020 was $10.3 million (down 17.26% YoY) and the FY2019 annual result came in at $10.3 million, changed N/A from the prior year.
Invested Capital advanced to $10.3 million in Q4 2019, from $1.2 million in the prior quarter.
In the past five years, Invested Capital ranged from a high of $11.2 million in Q1 2019 to a low of $1.2 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	190.90 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	2.57 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	380.00 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Summit Therapeutics	10.59 Bn	9.90 Bn	-	-

Download Data